Sylentis
SYL040012 is an siRNA designed to inhibit adrenergic receptor beta-2. Sylentis’ first RNAi drug candidate, the glaucoma therapy began a phase I trial in September.
...
04 diciembre 2009
Farmacos en Ensayos Clinicos basados en RNAi . Uno de ellos nuestro Farmaco para Glaucoma SYL040012 .
Sylentis
SYL040012 is an siRNA designed to inhibit adrenergic receptor beta-2. Sylentis’ first RNAi drug candidate, the glaucoma therapy began a phase I trial in September.
...